How Weight Bias and Stigma Undermine Healthcare Access and Utilization.

Purpose Of Review: To highlight recent evidence of the impact of weight bias and stigma on healthcare access and utilization.

Recent Findings: Healthcare access for patients with obesity is limited by weight-discriminatory policies such as body mass index cutoffs and weight loss requirements. These policies are based on flawed justifications without demonstrated medical benefits.

Characterizing the antibody response to amustaline/glutathione pathogen-reduced red blood cells.

Background: The clinical significance of natural and treatment-emergent antibodies specific for amustaline/glutathione pathogen-reduced red blood cells (PRRBCs) is not known.

Study Design And Methods: A Phase 3, randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with conventional RBCs in cardiac or thoracic-aorta surgery. Subjects transfused during and for 7 days after surgery were screened for PRRBC-specific antibodies at baseline, 28 and 75 days post-surgery.

Internalization of weight bias and stigma: Scientific challenges and opportunities.

Weight bias and stigma are widespread, unjust, and harmful to health. Increased empirical attention to the internalization of weight bias and stigma (or weight self-stigma) has revealed significant health implications that require further study and intervention. This review summarizes current knowledge on the conceptualization, measurement, prevalence, and correlates of internalized weight stigma.

Incidence and Risk Factors for Hypertension among Children with Nephrotic Syndrome.

Objectives: To determine incidence and risk factors for hypertension in childhood nephrotic syndrome.

Study Design: Using data from the Insight into Nephrotic Syndrome (INSIGHT) study, a prospective observational childhood nephrotic syndrome cohort from Toronto, Canada, we evaluated hypertension incidence and time-to-hypertension overall and stratified by 1) steroid-resistance or steroid-sensitivity, and 2) frequently-relapsing, steroid dependent, or infrequently-relapsing. Hypertension was defined as stage 1-2 hypertensive blood pressure on two consecutive visits or anti-hypertensive medication initiation.